Clinical Observation Of EGFR-TKI Combined With Chemotherapy For Advanced NSCLC

ObjectiveLung cancer is one of the tumors with the highest incidence and mortality in the world,among which,about 80-85% of the patients with lung cancer are non-small cell lung cancer（NSCLC）.The essence of EGFR gene is a kind of transmembrane glycoprotein combined by multiple amino acid combinations.It is widely found in the cell membrane of various human cells,which can promote tumor growth and induce angiogenesis,and it is also closely related to tumor invasion,migration and epithelial-mesenchymal transforma-tion^[10].The purpose of this study was to evaluate the clinical efficacy and safety of eg FR-tyrosine kinase inhibitor（EGFR-TKI）combined with chemotherapy in the treatment of non-small cell lung cancer（NSCLC）with EGFR-sensitive gene mutation,so as to provide data support for the clinical application of EGFR-TKI combined with chemotherapy.MethodsA total of 64 NSCLC patients admitted to our hospital from January 2017 to December 2019 were included in this study.All the enrolled patients were confirmed as EGFR gene-sensitive mutations by genetic testing,and the general data of all the patients were statistically compared.According to the principle of random allocation,64 patients were divided into the combination therapy group and the TKIs monotherapy group.Combined treatment group patients four cycles of chemotherapy,and each of 21 days for a cycle,in lung adenocarcinoma patients given carboplatin and pemetrexed in lung squamous carcinoma patients given carboplatin and he dorsey,remove the day before and after chemotherapy and chemotherapy treatment time of the rest of the day,daily oral EGFR TKIs-the treatment（for,for it,or he）,4 weeks after chemotherapy,patients still daily oral EGFR TKIs until in progression or the side reaction of intolerance and even death.For patients in the TKIs monotherapy group,EGFR-TKIs（geffitinib,Erlotinib or Ellotinib）were taken orally only on a daily basis until the disease progressed or intolerant side effects or even death occurred.Progression-free survival（PFS）,treatment effects including effective rate（ORR）,disease control rate（DCR）and adverse reaction rate were recorded and compared between the two groups.ResultsAfter comparing the general data,there was no statistical difference between the two groups（P>0.05）,and there was comparability.Compared with the EGFR-TKIS monotherapy group,ORR and DCR in the embedded combination therapy group were significantly improved（P<0.05）,and the mean PFS of patients with advanced NSCLC was significantly improved（P<0.01）.In the egfr-tkis combined with chemotherapy embedded treatment group,adverse events occurred,but were alleviated after treatment with corresponding measures,and there was no statistically significant difference in the incidence of adverse events（P>0.05）.ConclusionThis study found that clinical take EGFR TKIs-in conjunction with platinum chemotherapy drugs,and EGFR TKIs compared single drug group,combination group can significantly prolong the progression-free survival of patients with advanced NSCLC,efficient and control are significantly improved,also combination group of patients with rare hematology toxicity and gastrointestinal reaction,etc.,and 1-2 levels of adverse events,take relevant treatment after all can alleviate or even eliminate.The combined drug group can obtain better clinical efficacy,improve the quality of life of patients and their families,and has higher clinical application value.